Dr. Qu Zhican, Chairman of Nanolattix, was invited to attend the Supply and Demand Matching Conference for Nuclear Medical Industry Technology Achievements of China (Mianyang) Science and Technology City.
Release time:
2025-10-21
On October 15, 2025, the Supply and Demand Matching Conference for Nuclear Medical Industry Technology Achievements of China (Mianyang) Science and Technology City was successfully held in Chengdu. Mr. Huang Ping, Secretary-General of the National Atomic Energy Agency; Mr. Ge Xiaopeng, Deputy Secretary-General of the Provincial Government; and Mr. Li Yun, Deputy Secretary of the Municipal Party Committee and Mayor, attended and delivered speeches. Dr. Qu Zhican, Chairman of Nanolattix, was invited to attend the conference and deliver a keynote speech. Together with over 300 representatives from the National Atomic Energy Agency, provincial departments, industry associations, research institutes, and pharmaceutical enterprises, they discussed strategies for the high-quality development of the nuclear medicine industry.
In his speech, Dr. Qu Zhican highlighted Nanolattix's innovative achievements in the field of RDC (Radiopharmaceutical Drug Conjugate). The company's independently developed first-in-class drug RT01, which targets tumor antibodies and chelates lutetium-177 (Lu-177), possesses dual functions of treatment and tracing. Preclinical studies have demonstrated its excellent anti-tumor efficacy and favorable safety profile. The development of RDC drugs integrates life sciences, medical sciences, and nuclear physics. As an innovative practice in the medical field, it offers the advantages of combining diagnosis and therapy while enabling precise internal radiotherapy. During the conference, Dr. Qu Zhican engaged in in-depth exchanges with multiple institutions to further align needs and accelerate the implementation of innovative radiopharmaceuticals.
This achievement showcase fully demonstrates Nanolattix's professional expertise in the field of innovative radiopharmaceutical R&D. Nanolattix will continue to deepen its R&D strategy, strengthen collaboration with partners across the industrial chain, accelerate the development of RT01, and enhance its competitiveness in the nuclear medicine industry, thereby contributing to the advancement of Healthy China.
Tag:
recommend News
Share
